Are you Dr. Cooling?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 50 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
University Hospital, L4
Stony Brook, NY 11794Phone+1 631-444-2499- Is this information wrong?
Summary
- Dr. David Cooling, MD is an emergency medicine physician in Stony Brook, New York. He is currently licensed to practice medicine in New York. He is affiliated with Stony Brook University Hospital.
Education & Training
- NYU Long Island School of MedicineResidency, Internal Medicine, 1984 - 1987
- Stony Brook University Health Sciences Center School of MedicineClass of 1984
Certifications & Licensure
- NY State Medical License 1988 - 2014
Publications & Presentations
PubMed
- 31 citationsImproved specificity of myoglobin plus carbonic anhydrase assay versus that of creatine kinase-MB for early diagnosis of acute myocardial infarction.Gerard X Brogan, Juhani Vuori, Solomon Friedman, Charles F McCuskey, Henry C. Thode, H.Kalervo Vaananen, David S Cooling, Jay L. Bock> ;Annals of Emergency Medicine. 1996 Jan 1
- 74 citationsEvaluation of a New Rapid Quantitative Immunoassay for Serum Myoglobin Versus CK-MB for Ruling Out Acute Myocardial Infarction in the Emergency DepartmentGerard X Brogan, Solomon Friedman, Charles F McCuskey, David S Cooling, Luis Berrutti, Henry C. Thode, Jay L. Bock> ;Annals of Emergency Medicine. 1994 Oct 1
- 43 citations"Abnormal" electrocardiograms in patients with cocaine-associated chest pain are due to "normal" variantsJudd E. Hollander, Michael Lozano, Phillip Fairweather, Evan Goldstein, Paul Gennis, Gerard X. Brogan, David S Cooling, Henry C. Thode, E. John Gallagher> ;The Journal of Emergency Medicine. 1994 Mar 1
- Join now to see all
Press Mentions
- Genentech Reports Positive Data from Phase 2 CITYSCAPE Trial of Tiragolumab for Non-Small Cell Lung CancerMay 29th, 2020
- FDA Approves Genentech’s Tecentriq in Combination with Avastin for People with the Most Common Form of Liver CancerMay 29th, 2020
Hospital Affiliations
- Stony Brook University HospitalStony Brook, New York